Gratwohl A, Passweg J, Baldomero H, Hermans J
Department of Internal Medicine, Kantonsspital Basel, Switzerland.
Bone Marrow Transplant. 1998 Aug;22(3):227-40. doi: 10.1038/sj.bmt.1701329.
Transplant activity by members of the European Group for Blood and Marrow Transplantation (EBMT) and related European teams is reported for 1996 by indication, donor type and stem cell source. Bearing in mind reports from previous years, the annual numbers of transplants for each indication, transplant rates for each participating country, changes in transplant rates by indication and changes in donor types and stem cell sources are described. A total 14,593 blood or marrow transplants, performed in Europe by 382 teams from 31 countries, were reported in 1996. Of these, 4393 (30%) were allogeneic and 10,200 (70%) were autologous transplants. Of the autologous transplants, 978 (10%) were bone marrow derived, 9222 (90%) from peripheral blood stem cells or combined bone marrow and peripheral blood stem cell transplants. Of the allogeneic transplants, 3252 (74%) were bone marrow and 1141 (26%) were peripheral blood stem cell transplants. Main indications in 1996 were leukemias with 4961 transplants (34%), 70% allogeneic and 30% autologous; lymphomas with 5505 transplants (38%), 6% allogeneic and 94% autologous; solid tumours with 3484 transplants (24%), 1% allogeneic and 99% autologous; non-malignant disorders with 643 transplants (4%), 92% allogeneic and 8% autologous. There are major differences between countries. Transplant rates per 10m inhabitants per country ranged from 0 to >500 (median 202 per 10 m inhabitants). The most pronounced increase since 1990 for new indications in autologous transplants was observed in multiple myeloma and carcinoma of the breast. These data reflect recent changes and present status of blood and marrow transplantation in Europe. They provide a basis for patient counselling and health care planning.
欧洲血液与骨髓移植组（EBMT）成员及相关欧洲团队1996年的移植活动按适应症、供体类型和干细胞来源进行了报告。考虑到前几年的报告，描述了每种适应症的年度移植数量、每个参与国家的移植率、按适应症划分的移植率变化以及供体类型和干细胞来源的变化。1996年，来自31个国家的382个团队在欧洲共进行了14593例血液或骨髓移植。其中，4393例（30%）为同种异体移植，10200例（70%）为自体移植。在自体移植中，978例（10%）来自骨髓，9222例（90%）来自外周血干细胞或骨髓与外周血干细胞联合移植。在同种异体移植中，3252例（74%）为骨髓移植，1141例（26%）为外周血干细胞移植。1996年的主要适应症为白血病，共进行了4961例移植（34%），其中70%为同种异体移植，30%为自体移植；淋巴瘤5505例移植（38%），6%为同种异体移植，94%为自体移植；实体瘤3484例移植（24%），1%为同种异体移植，99%为自体移植；非恶性疾病643例移植（4%），92%为同种异体移植，8%为自体移植。各国之间存在重大差异。每个国家每1000万居民的移植率从0到>500不等（中位数为每1000万居民202例）。自1990年以来，自体移植新适应症中增长最为显著的是多发性骨髓瘤和乳腺癌。这些数据反映了欧洲血液和骨髓移植的近期变化和现状。它们为患者咨询和医疗保健规划提供了依据。
